Literature DB >> 29194001

Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers.

Nina A Bickell1, Jenny J Lin1, Sarah R Abramson1, Gerald P Hoke1, William Oh1, Simon J Hall1, Richard Stock1, Kezhen Fei1, Ann Scheck McAlearney1.   

Abstract

PURPOSE: Black men are more likely to die as a result of prostate cancer than white men, despite effective treatments that improve survival for clinically significant prostate cancer. We undertook this study to identify gaps in prostate cancer care quality, racial disparities in care, and underlying reasons for poorer quality care.
METHODS: We identified all black men and random age-matched white men with Gleason scores ≥ 7 diagnosed between 2006 and 2013 at two urban hospitals to determine rates of treatment underuse. Underuse was defined as not receiving primary surgery, cryotherapy, or radiotherapy. We then interviewed treating physicians about the reasons for underuse.
RESULTS: Of 359 black and 282 white men, only 25 (4%) experienced treatment underuse, and 23 (92%) of these were black. Most (78%) cases of underuse were due to system failures, where treatment was recommended but not received; 38% of these men continued receiving care at the hospitals. All men with treatment underuse due to system failures were black.
CONCLUSION: Treatment rates of prostate cancer are high. Yet, racial disparities in rates and causes of underuse remain. Only black men experienced system failures, a type of underuse amenable to health information technology-based solutions. Institutions are missing opportunities to use their health information technology capabilities to reduce disparities in cancer care.

Entities:  

Mesh:

Year:  2017        PMID: 29194001      PMCID: PMC5765902          DOI: 10.1200/JOP.2017.025957

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  32 in total

1.  Changes in Self-reported Insurance Coverage, Access to Care, and Health Under the Affordable Care Act.

Authors:  Benjamin D Sommers; Munira Z Gunja; Kenneth Finegold; Thomas Musco
Journal:  JAMA       Date:  2015-07-28       Impact factor: 56.272

2.  A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.

Authors:  Koichiro Akakura; Hiroyoshi Suzuki; Tomohiko Ichikawa; Hiroyuki Fujimoto; Osamu Maeda; Michiyuki Usami; Daisaku Hirano; Yukie Takimoto; Toshiyuki Kamoto; Osamu Ogawa; Yoshiteru Sumiyoshi; Jun Shimazaki; Tadao Kakizoe
Journal:  Jpn J Clin Oncol       Date:  2006-11-02       Impact factor: 3.019

3.  Comparing Prostate Cancer Treatment Decision Making in a Resource-rich and a Resource-poor Environment: A Tale of two Hospitals.

Authors:  Daniel M Walker; Ann Scheck McAlearney; Lindsey N Sova; Jenny J Lin; Sarah Abramson; Nina A Bickell
Journal:  J Natl Med Assoc       Date:  2016-09-15       Impact factor: 1.798

4.  Lessons From Early Implementation of a Patient-Centered Care Model in Oncology.

Authors:  Manasi A Tirodkar; Nicole Acciavatti; Lindsey M Roth; Ellen Stovall; Shelley Fuld Nasso; John Sprandio; Susan Tofani; Maureen Lowry; Mark W Friedberg; Aaron Smith-McLallen; Johann Chanin; Sarah Hudson Scholle
Journal:  J Oncol Pract       Date:  2015-09-29       Impact factor: 3.840

5.  External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older.

Authors:  Mara A Schonberg; Roger B Davis; Ellen P McCarthy; Edward R Marcantonio
Journal:  J Am Geriatr Soc       Date:  2011-07-28       Impact factor: 5.562

Review 6.  Improving modern cancer care through information technology.

Authors:  Steven B Clauser; Edward H Wagner; Erin J Aiello Bowles; Leah Tuzzio; Sarah M Greene
Journal:  Am J Prev Med       Date:  2011-05       Impact factor: 5.043

7.  National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.

Authors:  Michael W Drazer; Sandip M Prasad; Dezheng Huo; Mara A Schonberg; William Dale; Russell Z Szmulewitz; Scott E Eggener
Journal:  Cancer       Date:  2014-02-12       Impact factor: 6.860

8.  Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer.

Authors:  Kendra Schwartz; Isaac J Powell; Willie Underwood; Julie George; Cecilia Yee; Mousumi Banerjee
Journal:  Urology       Date:  2009-12       Impact factor: 2.649

9.  Racial variation in the quality of surgical care for prostate cancer.

Authors:  Daniel A Barocas; Darryl T Gray; Jay H Fowke; Nathaniel D Mercaldo; Jeffrey D Blume; Sam S Chang; Michael S Cookson; Joseph A Smith; David F Penson
Journal:  J Urol       Date:  2012-08-16       Impact factor: 7.450

10.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

View more
  1 in total

Review 1.  Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview.

Authors:  Nobuyuki Hinata; Masato Fujisawa
Journal:  World J Mens Health       Date:  2022-01-01       Impact factor: 5.400

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.